Sandoz is to appeal a court decision preventing it from launching a cheaper biosimilar competitor to Amgen’s Enbrel (etanercept) inflammatory diseases drug in the US, three years after approval ...

The Enbrel biosimilar, which is branded as Erelzi ... and could free up cash in the US health system that could be spent on newer drugs as well as widening access to biologic medicines.

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

The first round of Medicare prescription drugs negotiations covered Eliquis, Enbrel, Entresto, Farxiga, Fiasp/NovoLog; Imbruvica, Januvia, Jardiance, Stelara and Xarelto. Lower prices of those ...